<DOC>
	<DOCNO>NCT00552370</DOCNO>
	<brief_summary>To compare frequency severe hypoglycemia event 5 dose algorithm Lantus® , vary intensity define end-of -study target self monitor plasma glucose ( SMPG ) , patient Type 2 diabetes mellitus , inadequate glycemic control ( A1C great equal 7.0 % ) oral antidiabetic drug therapy ( OAD ) .</brief_summary>
	<brief_title>Glycemic Optimization Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Subjects must give sign informed consent . 2 . Diagnosis Type 2 DM least 6 month . 3 . Males female great equal 18 year age . 4 . A1c great equal 7.0 % . 5 . Current ( last 2 month ) diabetes therapy oral antihyperglycemia agent . 6 . Demonstrated willingness ability inject insulin glargine . 7 . Able understand willing comply procedure require protocol access phone . 8 . Demonstrated ability willingness perform selfmonitoring blood glucose ( SMBG ) use algorithm calculator ( ALCAL ) . 9 . BMI great 25.0 kg/m2 . 10 . Subjects , opinion investigator , initiated insulin therapy . 1 . Cardiac status New York Heart Association ( NYHA ) IIIIV ( Appendix A ) . 2 . For subject treat metformin ( Glucophager , Glucophage XRr , Glucovancer , Metaglipr , Avandametr ) plus serum creatinine great 1.5 mg/dL ( 133 μmol/L ) males great 1.4 mg/dL ( 124 μmoL ) female , inability unwillingness discontinue medication , remain entire study . 3 . For subject thiazolidinediones , inability unwillingness discontinue medication remain entire study . 4 . Planned pregnancy , pregnancy , lactation . 5 . Serum creatinine great 3.0 mg/dL ( 266 μmol/L ) . 6 . Serum glutamic pyruvic transaminase ( SGPT ) great 2.5 x upper limit normal range . 7 . Any current malignancy cancer within past 5 year ( except adequately treat basal cell carcinoma cervical carcinoma situ ) . 8 . Diagnosis dementia mental condition render subject unable understand nature , scope , possible consequence study . 9 . Hypersensitivity Lantus® insulin component . 10 . Any disease condition , include abuse illicit drug , prescription medicine , alcohol , opinion sponsor/investigator , may interfere completion study . 11 . Current ( last 2 month ) insulin therapy . 12 . With exception thiazolidinediones ( potential subject ) subject take metformin exclusionary creatinine level , ability unwillingness continue prestudy antihyperglycemia agent prestudy dosage entire study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>